| Filed On | Filing |
|---|---|
| 10 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
GAITHERSBURG, Md., November 5, 2026 – Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended September 30, 2026. |
| 29 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease1 |
| 16 Oct 2026 | SCHEDULE 13G |
| 16 Oct 2026 | SCHEDULE 13D/A |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | FORM S-8 |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Press Release Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights • Reported total revenue of $57 million for the second quarter of 2026 and raised full- year 2026 Revenue Framework • Improved GAAP Combined R... |
| 06 Aug 2026 | 10-Q |
| 23 Jun 2026 |
Form 4: Rodgers Richard J, Director
Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units · Received 18,880 shares by exercise or conversion |
| 23 Jun 2026 |
Form 4: King Rachel K., Director
Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units · Received 18,880 shares by exercise or conversion |
| 23 Jun 2026 |
Form 4: Douglas Richard, Director
Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units · Received 18,880 shares by exercise or conversion |
| 23 Jun 2026 |
Form 4: Mcglynn Margaret G, Director
Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units · Received 18,880 shares by exercise or conversion |
| 23 Jun 2026 |
Form 4: Mott David M, Director
Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units · Received 18,880 shares by exercise or conversion |
| 23 Jun 2026 |
Form 4: Alton Gregg H, Director
Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units · Received 18,880 shares by exercise or conversion |
| 23 Jun 2026 |
Form 4: Shiver John W., Director
Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units |
| 23 Jun 2026 |
Form 4: Newton Charles W., Director
Granted 21,270 Stock Option (Right to Buy) · Granted 14,180 Restricted Stock Units |
| 23 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2026, Novavax, Inc. (the “Company”) held its Annual Meeting, at which stockholders as of April 23, 2026 (the “Record Date”) were entitled to vote. As of the Record Date, there were 164,427,429 shares of the Company’s common s... |
| 27 May 2026 | 144 |
Loading...